The field of pharmacometrics has been responsible for countless
advancements within the drug development space. In recent years, we have
witnessed the implementation of both new and revived analytical methods
to increase clinical trial success and even supplement the need for
clinical trials all together. Throughout this article we will explore
the path of pharmacometrics from its inception to present day. At this
point in time, the target of drug development has been the average
patient, and population approaches have primarily been utilized to
support just that. The challenge we are now facing involves the
translation from treating the typical patient to treating the real-world
patient. For this reason, it is our opinion that future development
efforts should account more for the individual. With advanced
pharmacometric methods and growing technological infrastructure,
precision medicine can become a development priority rather than a
clinician's burden.